Back to resultsTyrosine for Methamphetamine Dependence - 1
Primary Purpose
Amphetamine-Related Disorders
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Tyrosine
Sponsored by
About this trial
This is an interventional treatment trial for Amphetamine-Related Disorders focused on measuring amphetamine dependence
Eligibility Criteria
Inclusion Criteria: 18-65 years of age. Able to provide informed consent. Desire to reduce/eliminate methamphetamine use. Used within the past two weeks. Meet DSM criteria for methamphetamine dependence. Exclusion Criteria: No dependence (within the past 12 months) for other durgs except nicotine. No history or family history of tyrosine intolerance.
Sites / Locations
- Haight Ashbury Free Clinics
Outcomes
Primary Outcome Measures
Craving
Drug use
Retention
Functioning
Secondary Outcome Measures
Full Information
NCT ID
NCT00000322
First Posted
September 20, 1999
Last Updated
January 11, 2017
Sponsor
National Institute on Drug Abuse (NIDA)
1. Study Identification
Unique Protocol Identification Number
NCT00000322
Brief Title
Tyrosine for Methamphetamine Dependence - 1
Official Title
Tyrosine for Methamphetamine Dependence
Study Type
Interventional
2. Study Status
Record Verification Date
April 1997
Overall Recruitment Status
Completed
Study Start Date
April 1997 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2001 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
National Institute on Drug Abuse (NIDA)
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions. Examine effect of tyrosine on abstinence, retention in treatment, and craving."
Detailed Description
Evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions. Examine effect of tyrosine on abstinence, retention in treatment and craving.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Amphetamine-Related Disorders
Keywords
amphetamine dependence
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Masking
Double
Allocation
Randomized
Enrollment
89 (false)
8. Arms, Groups, and Interventions
Intervention Type
Behavioral
Intervention Name(s)
Tyrosine
Primary Outcome Measure Information:
Title
Craving
Title
Drug use
Title
Retention
Title
Functioning
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18-65 years of age. Able to provide informed consent. Desire to reduce/eliminate methamphetamine use. Used within the past two weeks. Meet DSM criteria for methamphetamine dependence.
Exclusion Criteria:
No dependence (within the past 12 months) for other durgs except nicotine. No history or family history of tyrosine intolerance.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gantt Galloway, Pharm.D.
Organizational Affiliation
Haight Ashbury Free Clinics
Official's Role
Principal Investigator
Facility Information:
Facility Name
Haight Ashbury Free Clinics
City
San Francisco
State/Province
California
ZIP/Postal Code
94117
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Tyrosine for Methamphetamine Dependence - 1
We'll reach out to this number within 24 hrs